MELOXICAM - THERAPEUTIC ADVANCE BY PREFER ENTIAL COX-2 INHIBITION

Evaluation of Study Results in Osteoarthrosis (OA). Due to the princip le of action of meloxicam, namely, preferential COX-2 inhibition, it i s expected that this preparation represents a therapeutic advance in t he treatment of degenerative and inflammatory rheumatic diseases. The present summarising assessment shows on the basis of a large number of cases (a total of 2,992 patients) of activated arthroses of the verte bral joints and joints of the extremities, that meloxam given in doses of 7.5 and 15 mg is equally effective as the conventional NSAR diclof enac 100 mg retard and piroxicam 20 mg. At the same time it could also be proven that meloxicam is definitely much better tolerated than the other substances under test, and that it reduces the incidence of und esirable gastrointestinal disturbances to a statistically significant extent.